Skip to main content
2024 PharmSci 360 Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Back

Discovery and Basic Research
Hot Topic

Hot Topic: Beyond the Hype: The Realities of AI in Drug Discovery

Wednesday, October 23, 2024
10:00 AM – 11:00 AM MT
Location:250 ABC

Discovery and Basic Research Hot Topic

Join us for an in-depth exploration of AI drug discovery, where we separate revolutionary advancements from rhetoric. Our presentation leverages insights from a three-decade career at the intersection of data science and biotech, including founding an AI-driven biotech that identified 21 theragnostics in just 15 months. We will unravel myths, spotlight unseen challenges, and showcase AI's real potential in revolutionizing healthcare. This conversation, brought to you by a pioneer with firsthand experience, is essential for anyone in the industry.

Who is Turing Biosciences LLC?

Founded in December 2022, Turing Biosciences is a Boston-based biotech company pioneering the convergence of AI drug discovery and pharmaceutical development. We address three epic problems: the undiscovered burden of disease, the inaccessibility of medications due to high costs, and prolonged drug discovery timelines. Utilizing DARPA-inspired, large-scale machine learning contests across integrated omics data, we rapidly discover and approve new drugs with unprecedented speed, efficacy, and safety.
Mission and Impact
Turing Biosciences is on a mission to transform healthcare, addressing profound challenges in diagnostics and treatments affecting billions globally. We are revolutionizing the industry by reducing drug discovery times from years to weeks and dramatically cutting development costs. Our work ensures that lifesaving medicines are accessible to all, irrespective of socio-economic status. We are not just a biotech company, but a beacon of hope, advocating for health as a fundamental human right and aiming for healthcare equity.
Presenter Background
Eric Luellen (MSc, MPH) is an accomplished businessman, serial entrepreneur, and scientist. He is the Chief Technology and Innovation Officer at Turing Biosciences. Before this role, he was the CTIO of a Series D microbiome company backed by Gates Ventures and the Bill & Melinda Gates Foundation. His accolades include being a global finalist for the 2016 C3 Prize at Stanford MedX and winning the 2017 American Startupbootcamp Digital Health Accelerator in China. Luellen holds advanced degrees and certificates from American University, Northwestern University, University of Massachusetts–Amherst, Harvard University, Wharton, MIT Sloan, Columbia, Caltech, and Harvard Law School.
Presentation Goals
Educational Insight: Provide a deep dive into the realities of AI in drug discovery, exploring what truly works and what doesn't.
Critical Analysis: Offer an insider's perspective on the AI drug discovery landscape, discussing common myths, overlooked challenges, and practical implications.
Innovation Highlight: Showcase real-world successes in AI-driven drug discovery, as evidenced by the speaker's experience in rapidly identifying significant numbers of theragnostics.
Industry Guidance: Navigate attendees through the complexities and hype surrounding AI in drug discovery, providing insights needed to identify genuine innovation.
Inspiration and Call to Action: Inspire attendees by demonstrating AI's transformative potential in drug discovery and encouraging a discerning, informed perspective.

Learning Objectives:

  • Identify key AI technologies in drug discovery, differentiate between hype and practical applications, and implement strategies for integrating AI into their research and development processes effectively.
  • Upon completion, participants will be able to critically evaluate AI-driven research findings, forecast emerging trends in AI drug discovery, and navigate the ethical considerations of AI integration in biotechnology.
  • Upon completion, participants will be able to articulate the challenges and successes of AI in drug discovery, fostering collaborative solutions and innovation in their professional networks and research initiatives.
  • Educational Insight: To provide a deep dive into the realities of AI in drug discovery, moving beyond the surface-level excitement to explore what truly works and what doesn’t. This includes a realistic assessment of AI’s current and future impact on the field
  • Critical Analysis: To offer a vital insider’s perspective on the AI drug discovery landscape, including a discussion of common myths, challenges that are often overlooked, and the practical implications of integrating AI into the drug discovery process.